Saccharomyces boulardii for the prevention of hospital onset clostridium difficile infection

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 1, 2015, Pages 21-24

  Flatley, Elizabeth A ^a   Wilde, Ashley M ^b   Nailor, Michael D ^a,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b Norton Healthcare   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

Clostridium difficile infection; Probiotics; Saccharomyces boulardii

Indexed keywords

CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLINDAMYCIN; LEVOFLOXACIN; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG CAPSULE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFECTION CONTROL; MICROBIAL IDENTIFICATION; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SACCHAROMYCES BOULARDII; TERTIARY CARE CENTER; CLASSIFICATION; CONNECTICUT; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; INTESTINE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROBIOLOGY; MIDDLE AGED; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PHYSIOLOGY; RISK FACTOR; SACCHAROMYCES; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CONNECTICUT; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; INTESTINES; MALE; MIDDLE AGED; PROBIOTICS; RETROSPECTIVE STUDIES; RISK FACTORS; SACCHAROMYCES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924103017     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69: 881-891. doi: 10. 1093/jac/dkt477.
2. Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea. Ann Intern Med 2012; 157: 878-888. doi: 10. 7326/0003-4819-157-12-201212180-00563.
3. Dubberke ER, Carling P, Carrico R, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35: 628-645. doi: 10. 1086/676023.
4. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-822. doi: 10. 1111/j. 1572-0241. 2006. 00465. x.
5. Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C. Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of Clostridium difficile disease. J Clin Microbiol 2010; 48: 2082-2086. doi: 10. 1128/JCM. 00129-10.
6. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435-438. doi: 10. 1086/525047.
7. Van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415. doi: 10. 1056/NEJMoa1205037.
8. Malkan AD, Scholand SJ. Preventing downstream Clostridium difficile infections with upstream antibiotic management. Med Hypotheses 2012; 78: 136-137. doi: 10. 1016/j. mehy. 2011. 10. 009.